Analysis of Clinical and Pathological Prognostic Factors for Recurrent Epithelial Ovarian Cancer
-
摘要: 目的 分析影响上皮性卵巢癌(epithelial ovarian cancer,EOC)复发患者预后的相关临床病理因素。方法 采用Kaplan-meier生存率曲线，Log rank检验和Cox模型多因素回归分析法对92例临床病理及随访资料完整的复发癌患者进行影响其预后的相关因素分析。结果 (1)92例复发上皮性卵巢癌临床病例的总体中位生存时间是18月(95%CI:16.052~19.948);(2) Kaplan-Meier单因素分析提示，FIGO 分期、复发距离末次化疗时间、复发部位、最大复发病灶、复发后伴有腹水、CA125升高、复发后二次肿瘤细胞减灭术、再次治疗化疗方案是影响复发EOC患者的重要预后因素(P<0.1)。而年龄、肿瘤细胞分级、初次治疗方案与预后无关(P>0.1);(3)Cox回归分析结果显独示，复发后再次治疗化疗方案、最大复发病灶大小、复发部位是影响患者预后的独立危险因素。结论 多个临床病理因素影响复发上皮性卵巢癌预后，其中复发后再次治疗化疗方案、最大复发病灶大小、复发部位是影响患者预后的独立危险因素。Abstract: Objective To analyze the clinical and pathological prognostic factors of recurrent epithelial ovarian cancer. Methods Kaplan-meier survival curves,Log-rank test and Cox multivariate test regression were used to analyze clinical and pathological prognostic factors of relapse epithelial ovarian cancer in 92 cases with recurrent epithelial ovarian cancer which clinical pathology and follow-up data was completed. Results (1) Ninety-two patients with recurrent epithelial ovarian carcinoma cases overall median survival time was 18 months (95%CI:16.065~19.948).(2) Kaplan-Meier univariate analysis showed that FIGO stage,recurrence time from the last chemotherapy,recurrence site,the largest recurrence lesion,relapse with ascites,CA125 increased,secondary cytoreductive surgery,chemotherapy program for recurrence was the impact of important prognostic factor for re-treatment patients with recurrent EOC(P<0.1).But there was no relationship between age,grade of tumor cell,initial treatment plan and prognosis(P>0.1).(3)The Cox regression analysis showed that re-treatment regimen after relapse,the maximum recurrence of tumor size,recurrence site was an independent prognostic risk factor. Conclusion There are multiple clinical and pathological factors for affecting prognosis of recurrence epithelial ovarian cancer.Re-treatment regimen after relapsed,the maximum recurrence of tumor size,recurrence site are independent prognostic risk factors.
-
Key words:
- Epithelial ovarian cancer /
- Tumor recurrence /
- Prognosis /
- Cox model
-
-
[1] Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300. [2] Matulonis UA,Horowitz NS,Campos SM,et al.Phase Ⅱ study of carboplatin and pemetrexed for the treatment ofplatinum-sensitive recurrent ovarian cancer[J].J Clin Oncol,2008,26(35):5761-6. [3] Sharma R,Graham J,Mitchell H,et al.Extended weekly dose-dense paclitaxel/ carboplatin is feasible and activein heavily pre-treated platinum-resistant recurrent ovarian cancer[J].B J Cancer,2009,100(5):707-12. [4] Hoekstra AV,Hurteau JA,Kirschner CV,et al.The combination of monthly carboplatin and weekly paclitaxel ishighly active for the treatment of recurrent ovarian cancer[J].Gynecol Oncol,2009,115(3):377-81. [5] Onda T,Yoshikawa H,Yasugi T,et al.Secondary cytoreductive surgery for recurrent epithelial ovariancarcinoma:proposal for patients selection[J].Br J Cancer,2005,92(6):1026-32. [6] Park JY,Eom JM,Kim DY,et al.Secondary cytoreductive surgery in the management of platinum-sensitiverecurrent epithelial ovarian cancer[J].J Surg Oncol,2010,101(5):418-24. [7] Rema PN,Suchetha S,Mathew AP,et al.Secondary cytoreduction in epithelial ovarian cancer recurrence:aperspective from a regional cancer center in India[J].J Reprod Med,2009,54(8):506-10. [8] Schorge JO,Wingo SN,Bhore R,et al.Secondary cytoreductive surgery for recurrent platinum-sensitive ovariancancer[J].Int J Gynaecol Obstet,2010,108(2):123-7. [9] Tian WJ,Jiang R,Cheng X,et al.Surgery in recurrent epithelial ovarian cancer:benefits on Survival forpatients with residual disease of 0.1-1 cm after secondary cytoreduction [J].J Surg Oncol,2010,101(3):244-50. [10] Zang RY,Harter P,Chi DS,et al.Predictors of survival in patients with recurrent ovarian cancer undergoingsecondarycytoreductive surgery based on the pooled analysis of an international collaborative cohort[J].Br JCancer,2011,105(7):890-6. [11] Wright JD,Herzog TJ,Powell MA,et al.Morbidity of cytoreductive surgery in the elderly[J].Am J ObstetGynecol,2004,190(5):1398-400. [12] Gadducci A,Cosio S,Zola P,et al.The clinical outcome of epithelial ovarian cancer patients with apparentlyisolated lymph node recurrence:a multicenter retrospective Italian study[J].Gynecol Oncol,2010,116(3):358-63.
计量
- 文章访问数: 2435
- HTML全文浏览量: 23
- PDF下载量: 684
下载:
